Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison

Published by: BCC Research

Published: Oct. 30, 2006 - 202 Pages

Table of Contents

INTRODUCTION

OBJECTIVES AND GOALS OF THE STUDY

CONTRIBUTION OF THE STUDY AND FOR WHOM

SCOPE AND CONTENT

METHODOLOGY

INFORMATION SOURCES

AUTHOR'S CREDENTIALS

RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS

EXECUTIVE SUMMARY

Summary Table:
GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)

Summary Figure:
GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, 2004-2011 ($ MILLIONS)

OVERVIEW

THE HERBAL SUPPLEMENT, PRESCRIPTION AND OVER-THE-COUNTER DRUG MARKETS

DEFINITION OF AN HERBAL SUPPLEMENT

U.S. REGULATIONS RELATING TO HERBAL SUPPLEMENTS

U.S. ISSUES FIRST HERBAL SUPPLEMENT STANDARDS

NONGOVERNMENT OVERSIGHT OF HERBAL PRODUCT QUALITY

OVERSEAS REGULATIONS RELATING TO HERBAL SUPPLEMENTS

REIMBURSEMENT FOR HERBAL PRODUCTS IN THE E.U.

THE WORLD HEALTH ORGANIZATION RELEASES GUIDELINES FOR MEDICINAL HERBS

SOURCES OF RAW MATERIALS FOR HERBAL SUPPLEMENTS

THE CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA

TERMS USED TO DESCRIBE THE SOURCES OF HERBS USED IN SUPPLEMENTS

USE OF HERBAL SUPPLEMENTS WORLDWIDE

CURRENT BEST-SELLING HERBAL SUPPLEMENTS AND INDICATIONS FOR HERBAL SUPPLEMENTS

FORECASTING BY PRODUCT

THE ACTIVE INGREDIENTS IN AND INDICATIONS FOR POPULAR HERBAL SUPPLEMENTS

Table 1 ACTIVE INGREDIENTS AND INDICATIONS FOR SELECTED POPULAR HERBAL SUPPLEMENTS

Table 1 (CONTINUED)

ADVERSE HERB-DRUG INTERACTIONS

LEADING HERBAL SUPPLEMENTS WORLDWIDE

BILBERRY

BLACK COHOSH

ECHINACEA

ELDERBERRY

ELEUTHERO

EVENING PRIMROSE

Table 2 CONCENTRATED SOURCES OF GLA

Evening Primrose (Continued)

GARLIC

Garlic (Continued)

GINGER

GINKGO

Ginkgo (Continued)

Ginkgo (Continued)

GINSENG

Ginseng (Continued)

Ginseng (Continued)

Table 3 AVERAGE PRICE PER DRY POUND OF GINSENG, BASED ON THE SOURCE OF THE ROOT ($/LB.)

Ginseng (Continued)

GOLDENSEAL

GRAPE SEED EXTRACT

GREEN TEA

Green Tea (Continued)

HORNY GOAT WEED

KAVA KAVA

MILK THISTLE

PYGEUM

ST. JOHN'S WORT

St. John's Wort (Continued)

SAW PALMETTO

Saw Palmetto (Continued)

SOY

Soy (Continued)

VALERIAN

YOHIMBE

THE PRESCRIPTION DRUG INDUSTRY

APPLICATIONS AND PRODUCTS

HERBAL SUPPLEMENT AND PRESCRIPTION DRUG MARKETS TO TREAT SELECTED DISEASES AND CONDITIONS

Table 4 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS FOR DISEASES, THROUGH 2011 ($ MILLIONS)

Table 5 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)

Figure 1 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)

Table 6 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)

Figure 2 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)

THE GLOBAL MARKET FOR HERBAL SUPPLEMENTS

Table 7 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, THROUGH 2011 ($ MILLIONS)

Figure 3 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, 2004-2011 ($ MILLIONS)

Table 8 ESTIMATED GLOBAL MARKET FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)

THE U.S. MARKET FOR HERBAL SUPPLEMENTS

Top-Selling Herbal Supplements in the U.S.

Table 9 THE TOP-SELLING HERBAL SUPPLEMENTS IN THE U.S. MARKET IN 2002 THROUGH FOOD, DRUG AND MASS MARKET CHANNELS ($ MILLIONS)

Table 10 U.S. MARKET FORECAST FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)

Table 11 PERCENTAGE OF THE U.S. HERBAL SUPPLEMENTS MARKET HELD BY MULTIPLE-HERB FORMULAS, 2003-2005 (%)

SALES OF HERBAL SUPPLEMENTS IN THE U.S. BY DISTRIBUTION CHANNEL

Table 12 U.S. MARKET FORECAST FOR SALES OF HERBAL TREATMENTS, BY DISTRIBUTION CHANNEL, THROUGH 2011 ($ MILLIONS)

Table 13 THE TOP-SELLING HERBAL SUPPLEMENTS SOLD THROUGH FOOD, DRUG AND MASS MARKET CHANNELS IN THE U.S, 2004 AND 2005 ($ MILLIONS)

PRESCRIPTION PHARMACEUTICAL PRODUCTS

BEST-SELLING DRUGS IN 2005

BENIGN PROSTATIC HYPERPLASIA

HERBAL SUPPLEMENTS FOR THE TREATMENT OF BPH

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT BPH

Table 14 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS TO TREAT BPH

Prescription Drugs to Treat BPH (Continued)

Generic Proscar Introduced

The Market for Prescription Drugs to Treat BPH

Table 15 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)

Figure 4 MARKET SHARE OF PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, 2005 (%)

Figure 4 (CONTINUED)

Table 16 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT BPH

Table 17 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF BPH

BXL 628

Cetrorelix

Lonidamine

QLT-0087

Silodosin

Tadalafil

COGNITIVE DISORDERS

HERBAL SUPPLEMENTS TO TREAT COGNITIVE DISORDERS

THE MARKET FOR HERBAL SUPPLMENTS TO TREAT COGNITIVE DISORDERS

Table 18 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT COGNITIVE DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS

THE MARKET FOR PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS

Table 19 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 20 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, THROUGH 2011 ($ MILLIONS)

DRUGS IN DEVELOPMENT TO TREAT COGNITIVE DISORDERS

Table 21 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF COGNITIVE DISORDERS

Namenda

Alzhemed

Flurizan

Namenda

Neramexane

DEPRESSION

DEPRESSION (Continued)

DEPRESSION (Continued)

HISTORY OF ANTIDEPRESSANT MEDICATIONS

HERBAL SUPPLEMENTS TO TREAT DEPRESSION

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT DEPRESSION

Table 22 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT DEPRESSION, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS TO TREAT DEPRESSION

Cymbalta

Effexor/Effexor Xr

Lexapro

Remeron

Wellbutrin/Wellbutrin SR/Wellbutrin XL

Zoloft

Generic Versions of Best-selling Antidepressants

Revived Interest in Older Antidepressants

Antidepressants Recently Withdrawn From the Market

FDA Issues Warning on Use of Antidepressants in Children and Adolescents, and Perhaps Adults

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT DEPRESSION

Table 23 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 24 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)

Figure 5 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)

PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT DEPRESSION

Table 25 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF DEPRESSION

Table 25 (CONTINUED)

DVS-233 SR

ERECTILE DYSFUNCTION

HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION

Table 26 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT ERECTILE DYSFUNCTION, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION

Marketed Products

Cialis

Levitra

Viagra

Zydena

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION

Table 27 GLOBAL MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 28 U.S. MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

DRUGS IN DEVELOPMENT TO TREAT ERECTILE DYSFUNCION

Table 29 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ERECTILE DYSFUNCTION

TA-1790

Uprima

Vasomax

GASTROINTESTINAL DISORDERS

DYSPEPSIA

HEARTBURN/GASTROESOPHAGEAL REFLUX DISEASE

NAUSEA

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT GASTROINTESTINAL DISORDERS

Table 30 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)

PHARMACEUTICAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS

Antinauseants

Locally Acting Antienauseants

Centrally Acting Antinauseants

Antidopaminergics

Antidopaminergics (Continued)

Anticholinergics

Miscellaneous Antinauseants

Miscellaneous Antinauseants (Continued)

Table 31 MARKETED ANTINAUSEANT PRODUCTS

Market Size and Growth

Table 32 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)

Table 33 ESTIMATED U.S. MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)

H2 Inhibitors

The History of H2 Inhibitors

Marketed Prescription Products

Marketed Prescription Products (Continued)

Table 34 MARKETED H2 INHIBITORS

Market Size and Growth

Table 35 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)

Figure 6 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)

Table 36 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)

Figure 7 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)

Proton Pump Inhibitors

AcipHex/Pariet

Nexium

Prevacid/Takepron

Prilosec/Losec

Protonix/Pantozol/Protium

Zegerid

Generic Proton Pump Inhibitors

Comparison of Proton Pump Inhibitors

Table 37 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS

Cost of Proton Pump Inhibitors

The Market for Proton Pump Inhibitors

Table 38 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 39 U.S. MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 39 (CONTINUED)

Loss of Patent Protection by Leading Prescription Proton Pump Inhibitors

Table 40 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS, 2005-2013

Table 40 (CONTINUED)

Prescription Gastrointestinal Products in Development

Table 41 SELECTED GASTROINTESTINAL DISORDER TREATMENTS IN PHASE II OR LATER DEVELOPMENT

Prescription versus OTC Proton Pump Inhibitors

Over-the-Counter Gastrointestinal Products

Antacids

Antacids (Continued)

Systemic Antacids

Sodium Bicarbonate

Nonsystemic Antacids

Calcium Carbonate

Aluminum Products

Magnesium Products

Combination Products

Table 42 MARKETED OTC ANTACID PRODUCTS

Market Size and Growth

Table 43 U.S. MARKET FORECAST FOR OTC ANTACIDS, THROUGH 2011 ($ MILLIONS)

Antinauseants

Table 44 MARKETED OTC ANTINAUSEANTS

Market Size and Growth

Table 45 U.S. MARKET FORECAST FOR OTC ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)

H2 Inhibitors

Table 46 MARKETED OTC H2 INHIBITORS

Market Size and Growth

Table 47 ESTIMATED U.S. MARKET FOR OTC H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)

Proton Pump Inhibitors

Table 48 MARKETED OTC PROTON PUMP INHIBITORS

Market Size and Growth

Table 49 U.S. MARKET FORECAST FOR OTC PROTON PUMP INHIBITORS, THROUGH 2011 ($ MILLIONS)

HYPERCHOLESTEROLEMIA

HYPERCHOLESTEROLEMIA (Continued)

HYPERCHOLESTEROLEMIA (Continued)

RELATIONSHIP OF CHOLESTEROL TO CARDIOVASCULAR DISEASE

HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA

Beta Sitosterol

THE MARKET FOR HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA

Table 50 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

Table 51 CLASSES OF LIPID-LOWERING DRUGS

Table 52 LIPID-LOWERING DRUGS USED IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CORONARY ARTERY DISEASE

Bile Acid-binding Resins

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Marketed Statin Drugs

Table 53 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.

Fibric Acids

Nicotinic Acid and Derivatives

Probucol

Leading Products

Combination Products

Statin Drugs Show Promise in Treating Prostate Cancer

The Entry of Generic Versions of Blockbuster Cholesterol Drugs

The Medicare (Part D) Drug Benefit and Statin Drugs

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERCHOLESTEROLEMIA

Table 54 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 55 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

Table 56 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS

AGI-1067

CETi-1

ETC-588

ETC-642

FM-VP4

KS 01-019

Lipitor/Torcetrapib

MK-524B

The OTC Market for Statin Drugs

HYPERTENSION

HYPERTENSION (Continued)

HERBAL SUPPLEMENTS FOR THE TREATMENT OF HYPERTENSION

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT HYPERTENSION

Table 57 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT HYPERTENSION, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERTENSION

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERTENSION

Table 58 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 58 (CONTINUED)

Table 59 U.S. MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION

Table 60 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION

Aliskiren

Clevelox

Imidapril

PW2101

Tadalafil

INSOMNIA

Table 61 FREQUENCY OF INSOMNIA SYMPTOMS IN THE U.S. ADULT POPULATION (%)

HERBAL TREATMENTS FOR INSOMNIA

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT INSOMNIA

Table 62 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT INSOMNIA, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS FOR THE TREATMENT OF INSOMNIA

Ambien/ Ambien CR/ Stilnox

Benzodiazepines

Imovane

Lunesta

Rozerem

Sonata

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT INSOMNIA

Table 63 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 64 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT INSOMNIA

Table 65 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INSOMNIA

Ambien ODT

APD125

Eplivanaserin SR

Gaboxadol

Indiplon

Posidorm

OVER-THE-COUNTER TREATMENTS FOR INSOMNIA

Table 66 ESTIMATED U.S. MARKET FOR OTC PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)

MENOPAUSE

HERBAL TREATMENTS FOR MENOPAUSAL SYMPTOMS

Herbal Treatments for …(Continued)

THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT MENOPAUSAL SYMPTOMS

Table 67 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, BY HERB, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS

Prescription Drugs for the…(Continued)

THE MARKET FOR PRESCRIPTION DRUGS TO TREAT MENOPAUSAL SYMPTOMS

Table 68 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 69 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, THROUGH 2011 ($ MILLIONS)

PRESCRIPTION DRUGS IN DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS

Table 70 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS

Menopause Formula 101

INDUSTRY

LEADING PLAYERS IN THE NUTRITIONAL SUPPLEMENTS MARKET

Table 71 LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS

Table 72 MARKET SHARES OF LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS IN THE U.S., MARCH 2006 (%)

THE INTRODUCTION OF THE MEDICARE DRUG BENEFIT PLAN AND WHAT IT MEANS FOR DRUG SALES.

GENERIC DRUGS

THERAPEUTIC EQUIVALENCE

Table 73 FDA ORANGE BOOK THERAPEUTIC EQUIVALENCE RATING CODES

STATE POSITIVE FORMULARIES

BLOCKBUSTER AGENTS EXPERIENCING GENERIC CHALLENGE IN THE PRESCRIPTION PHARMACEUTICAL MARKET

BRAND-NAME COMPANIES ENTER ARRANGEMENTS WITH GENERICS FIRMS TO NOT INTRODUCE GENERIC VERSIONS OF BEST-SELLING DRUGS

THE INTRODUCTION OF AUTHORIZED GENERICS

The Introduction of …(Continued)

FDA BACKLOG IN REVIEWING GENERIC DRUG APPLICATIONS SLOWS THE ENTRY OF GENERIC DRUGS

THE RISE AND FALL IN GENERIC DRUG PRICES

GROWTH IN SALES OF GENERIC DRUGS

THE TRICKY GENERIC DRUG BUSINESS

STRATEGIES EMPLOYED BY GENERICS DRUG COMPANIES

First on the Market

Full ANDA Pipelines

Specialization and Niche Marketing

Specialization and …(Continued)

Successful Patent Challenges

Exclusive Providers

Exclusive Supplier Arrangements

Breadth of Product Line

Value-added Products

Proprietary Products

Supergenerics

Generic Biologicals

Mergers

Cost-effective Production

Cooperation with Branded Product Manufacturers

NOVARTIS TAKES THE LEAD AMONG GENERIC MANUFACTURERS

THE FDA ISSUES NEW GUIDELINES FOR DIRECT-TO-CONSUMER ADVERTISING

THE FDA ISSUES NEW …(Continued)

COMPANY PROFILES

HERBAL SUPPLEMENT COMPANIES

GNC CORPORATION

Business Overview

Financial Information

Products

Company Strategy

Business Overview

Financial Information

Products

Corporate Strategy

NATROL INC.

Business Overview

Financial Information

Products

Corporate Strategy

NATURAL ALTERNATIVES INTERNATIONAL

Business Overview

Financial Information

Products

Corporate Strategy

NATURE'S SUNSHINE PRODUCTS

Business Overview

Products

NBTY, INC.

Business Overview

Financial Information

Products

Corporate Strategy

NUTRACEUTICALS INTERNATIONAL

Business Overview

Financial Information

Products

Corporation Strategy

PHARMACEUTICAL COMPANIES

ABBOTT LABORATORIES

Business Overview

Financial Information

Products

Corporate Strategy

ATHEROGENICS, INC.

Business Overview

Financial Information

Products

Corporate Strategy

BIOVAIL, INC.

Business Overview

Financial Information

Products

Corporate Strategy

Corporate Strategy (Continued)

FOREST LABORATORIES

Business Overview

Financial Information

Products

Corporate Strategy

GLAXOSMITHKLINE PLC

Business Overview

Financial Information

Products

ICOS CORPORATION

Business Overview

Financial Information

Products

Corporate Strategy

PFIZER CORPORATION

Business Overview

Financial Information

Products

Corporate Strategy

SANTARUS, INC.

Business Overview

Products

Corporate Strategy

SEPRACOR INC.

Business Overview

ProductS

Corporate Strategy

Abstract

INTRODUCTION

The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify, qualify and compare the herbal supplement, prescription drug (including generics) and (where applicable) over-the-counter (OTC) drug markets for a variety of diseases with large patient bases.

This report offers a unique perspective on diseases for which herbal supplements as well as prescription drugs and, in some cases, OTC treatments are available. The purpose of the report is to compare trends in these treatment options and provide market assessments and forecasts for each. The information and analysis presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the healthcare, herbal supplement, prescription pharmaceutical and OTC treatment industry. The study provides a comprehensive analysis of the current markets for herbal supplements, prescription drugs and (where applicable) OTC products for the treatment of benign prostatic hyperplasia, cognitive disorders, depression, erectile dysfunction, gastrointestinal disorders (heartburn and nausea), hypercholesterolemia, hypertension, insomnia and menopausal symptoms.

SCOPE OF STUDY

This report contains:

• The major current and emerging markets for herbal supplements, prescription drugs and (where applicable) OTC treatments
• An overview section that provides a discussion of the emergence of the herbal supplements market, U.S. and overseas regulations and guidelines relating to this market, sources of raw materials and concerns about sustainability of herbal harvesting practices
• A global forecast for the herbal supplement and OTC market, with a five-year forecast date to 2011
• The latest company profiles for the top companies in the market
• A detailed patent analysis.

METHODOLOGY

The base year for this study is 2006. Figures are based on revenue numbers at the manufacturers' level and are projected at 2006 dollar value; that is, inflation is not computed into the projection figures.

This study was prepared with data and trends derived from herbal products specialists and organizations, pharmaceutical product managers, marketing strategists, research executives and others at leading herbal and pharmaceutical companies that have products used in the treatment of diseases covered in this report or which have products in development for these markets.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the herbal supplement/nutritional products and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from business literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.

AUTHOR'S CREDENTIALS

Lynn Gray has been a research analyst in the biotechnology and life sciences since 1989. Her collaboration with BCC Research began in 1996, and since then, she has authored over 20 BCC biomedical reports.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.